<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2413-4341</journal-id>
<journal-title><![CDATA[Revista Paraguaya de Reumatología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. parag. reumatol.]]></abbrev-journal-title>
<issn>2413-4341</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Paraguaya de Reumatología]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2413-43412024000200062</article-id>
<article-id pub-id-type="doi">10.18004/rpr/2024.10.02.62</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Frecuencia del Síndrome de anticuerpos Anti- fosfolípidos y su clasificación según los nuevos criterios EULAR 2023 en pacientes con Lupus Eritematoso Sistémico, que consultaron en el Departamento de Medicina Interna del Hospital Nacional, en el período 2020-2024]]></article-title>
<article-title xml:lang="en"><![CDATA[Frequency of Antiphospholipid Antibody Syndrome and its classification according to the new EULAR 2023 criteria in patients with Systemic Lupus Erythematosus Erythematosus, who consulted at the Internal Medicine Department of the National Hospital, in the period 2020-2024]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Montiel]]></surname>
<given-names><![CDATA[Dora]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Samudio]]></surname>
<given-names><![CDATA[Margarita]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Ministerio de Salud Pública y Bienestar Social Hospital Nacional de Itauguá ]]></institution>
<addr-line><![CDATA[Itauguá ]]></addr-line>
<country>Paraguay</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad del Pacífico  ]]></institution>
<addr-line><![CDATA[Asunción ]]></addr-line>
<country>Paraguay</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2024</year>
</pub-date>
<volume>10</volume>
<numero>2</numero>
<fpage>62</fpage>
<lpage>66</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.iics.una.py/scielo.php?script=sci_arttext&amp;pid=S2413-43412024000200062&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.iics.una.py/scielo.php?script=sci_abstract&amp;pid=S2413-43412024000200062&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.iics.una.py/scielo.php?script=sci_pdf&amp;pid=S2413-43412024000200062&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción: El síndrome antifosfolipídico (SAF), es una enfermedad autoinmune, sistémica, cuya expresión clínica se caracteriza por dos principales dominios, los eventos trombóticos, con trombosis venosa y/o arterial, y la morbilidad obstétrica, cuyas manifestaciones clínicas principales son la pérdida recurrente en el primer trimestre del embarazo, muerte fetal, pre-eclampsia, parto prematuro y restricción del crecimiento fetal, asociadas con la presencia de anticuerpos antifosfolipídicos (anticoagulante lúpico, anticuerpos anti-cardiolipina IgG/IgM, y/o anticuerpos anti-&#946; 2-glicoproteína I IgG/IgM).  Objetivo: Determinar la frecuencia del SAF y su clasificación según los nuevos criterios ACR/EULAR 2023, en pacientes con diagnóstico de lupus eritematoso sistémico (LES).  Materiales y Métodos: Estudio observacional, descriptivo, de corte transversal, de pacientes adultos con LES, que acudieron al Hospital Nacional, en el periodo comprendido entre enero-2020 y agosto-2024. El muestreo fue no probabilístico, por conveniencia. Fueron excluidos los pacientes con expedientes incompletos. Las variables analizadas fueron sociodemográficas, clínicas y de laboratorio.  Resultados: Se estudiaron 70 pacientes con diagnóstico de LES, entre 17 y 72 años de edad (media: 33,1 ± 12,3), 58 (82,80%) eran mujeres, 44 (62.8%) procedentes del Departamento Central, 36 (59%) con estudios secundarios, 15 pacientes (26.3%) tenían nefritis. De los mismos, 13 pacientes (18.5%) presentaron anticuerpos antifosfolipídicos. De acuerdo a los nuevos criterios en la cohorte de validación clasificaron como SAF: 5 pacientes (7.1%). Las manifestaciones clínicas presentadas por los 5 pacientes con SAF fueron trombosis venosa profunda en miembros inferiores 3/5 (60%), accidente cerebrovascular isquémico 1/5 (20%), endocarditis de Libman Sacks 1/5 (20%).  Conclusión: La frecuencia de anticuerpos antifosfolipídicos fue del 18.5% en pacientes con LES. De éstos, fueron clasificados con SAF, 5 pacientes. Las manifestaciones clínicas fueron la trombosis venosa profunda de miembros inferiores, el accidente cerebrovascular isquémico, y endocarditis de Libman-Sacks.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction: Antiphospholipid syndrome (APS) is a systemic autoimmune disease, whose clinical expression is characterized by two main domains, thrombotic events, with venous and/or arterial thrombosis, and obstetric morbidity, whose main clinical manifestations are recurrent loss in the first trimester of pregnancy, fetal death, pre-eclampsia, premature birth and fetal growth restriction, associated with the presence of antiphospholipid antibodies (lupus anticoagulant, anticardiolipin IgG/IgM antibodies, and/or anti-&#946; 2-glycoprotein I IgG/ IgM antibodies).  Objective: To determine the frequency of APS and its classification according to the new ACR/EULAR 2023 criteria, in patients diagnosed with systemic lupus erythematosus (SLE).  Materials and Methods: Observational, descriptive, cross-sectional study of adult patients with SLE, who attended the National Hospital, in the period between January 2020 and August 2024. The sampling was non-probabilistic, for convenience. Patients with incomplete records were excluded. The variables analyzed were sociodemographic, clinical and laboratory.  Results: 70 patients diagnosed with SLE were studied, between 17 and 72 years of age (mean: 33.1 ± 12.3), 58 (82.80%) were women, 44 (62.8%) from the Central Department, 36 (59%) with secondary studies, 15 patients (26.3%) had nephritis. Of these, 13 patients (18.5%) presented antiphospholipid antibodies. According to the new criteria in the validation cohort, 5 patients (7.1%) were classified as APS. The clinical manifestations presented by the 5 patients with APS were deep vein thrombosis in the lower limbs 3/5 (60%), ischemic stroke 1/5 (20%), and Libman-Sacks endocarditis 1/5 (20%).  Conclusion: The frequency of antiphospholipid antibodies was 18.5% in patients with SLE. Of these, 5 patients were classified with APS. The clinical manifestations were deep vein thrombosis of the lower limbs, ischemic stroke, and Libman-Sacks endocarditis.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Síndrome antifosfolipídico]]></kwd>
<kwd lng="es"><![CDATA[anticuerpos antifos-folipídicos]]></kwd>
<kwd lng="es"><![CDATA[clasificación Síndrome antifosfolipídico]]></kwd>
<kwd lng="en"><![CDATA[Antiphospholipid syndrome]]></kwd>
<kwd lng="en"><![CDATA[antiphospholipid antibodies]]></kwd>
<kwd lng="en"><![CDATA[classification of antiphospholipid syndrome]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Meroni]]></surname>
<given-names><![CDATA[PL]]></given-names>
</name>
<name>
<surname><![CDATA[Tsokos]]></surname>
<given-names><![CDATA[GC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Editorial: Systemic Lupus Erythematosus and Antiphospholipid Syndrome]]></article-title>
<source><![CDATA[Front Immunol]]></source>
<year>2019</year>
<volume>10</volume>
<page-range>199</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Paredes-Ruiz]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Martin-Iglesias]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Ruiz-Irastorza]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Thrombotic antiphospholipid syndrome: From guidelines to clinical management]]></article-title>
<source><![CDATA[Med Clin (Barc)]]></source>
<year>2024</year>
</nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Soto-Peleteiro]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Gonzalez-Echavarri]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Ruiz-Irastorza]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Obstetric antiphospholipid syndrome]]></article-title>
<source><![CDATA[Med Clin (Barc)]]></source>
<year>2024</year>
<volume>163</volume>
<numero>Suppl 1</numero>
<issue>Suppl 1</issue>
<page-range>S14-21</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schreiber]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Lykke]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Langhoff-Roos]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Nielsen]]></surname>
<given-names><![CDATA[HS]]></given-names>
</name>
<name>
<surname><![CDATA[Jacobsen]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antiphospholipid syndrome and pregnancy]]></article-title>
<source><![CDATA[Ugeskr Laeger]]></source>
<year>2016</year>
<volume>178</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>V09150730</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[De Simone]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Sciascia]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Fenoglio]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Oddone]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Barreca]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Roccatello]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antiphospholipid Syndrome and Kidney Involvement]]></article-title>
<source><![CDATA[Kidney Blood Press Res]]></source>
<year>2023</year>
<volume>48</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>666-77</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schreiber]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Hunt]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Managing antiphospholipid syndrome in pregnancy]]></article-title>
<source><![CDATA[Thromb Res]]></source>
<year>2019</year>
<volume>181</volume>
<numero>Suppl 1</numero>
<issue>Suppl 1</issue>
<page-range>S41-6</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fanouriakis]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kostopoulou]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Andersen]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Aringer]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Arnaud]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Bae]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[EULAR recommendations for the management of systemic lupus erythematosus: 2023 update]]></article-title>
<source><![CDATA[Ann Rheum Dis]]></source>
<year>2024</year>
<volume>83</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>15-29</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zuily]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Cervera]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Foret]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Bertocchi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Tincani]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Thrombocytopenia in antiphospholipid syndrome: Is anticoagulation and/or anti- aggregation always required?]]></article-title>
<source><![CDATA[Autoimmun Rev]]></source>
<year>2024</year>
<volume>23</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>103417</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wilson]]></surname>
<given-names><![CDATA[WA]]></given-names>
</name>
<name>
<surname><![CDATA[Gharavi]]></surname>
<given-names><![CDATA[AE]]></given-names>
</name>
<name>
<surname><![CDATA[Koike]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Lockshin]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<name>
<surname><![CDATA[Branch]]></surname>
<given-names><![CDATA[DW]]></given-names>
</name>
<name>
<surname><![CDATA[Piette]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop]]></article-title>
<source><![CDATA[Arthritis Rheum]]></source>
<year>1999</year>
<volume>42</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1309-11</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Miyakis]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Lockshin]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<name>
<surname><![CDATA[Atsumi]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Branch]]></surname>
<given-names><![CDATA[DW]]></given-names>
</name>
<name>
<surname><![CDATA[Brey]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
<name>
<surname><![CDATA[Cervera]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)]]></article-title>
<source><![CDATA[J Thromb Haemost]]></source>
<year>2006</year>
<volume>4</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>295-306</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barbhaiya]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Zuily]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Naden]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Hendry]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Manneville]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Amigo]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria]]></article-title>
<source><![CDATA[Arthritis Rheumatol]]></source>
<year>2023</year>
<volume>75</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1687-702</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aringer]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Costenbader]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Daikh]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Brinks]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Mosca]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ramsey- Goldman]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2019 European League Against Rheumatism/ American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus]]></article-title>
<source><![CDATA[Arthritis Rheumatol]]></source>
<year>2019</year>
<volume>71</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1400-12</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Amigo]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[García-Torres]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Robles]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bochicchio Reyes]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Afectación renal en el síndrome antifosfolípido primario]]></article-title>
<source><![CDATA[J Reumatol]]></source>
<year>1992</year>
<volume>19</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1181-5</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sciascia]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Montaruli]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Infantino]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antiphospholipid antibody testing]]></article-title>
<source><![CDATA[Med Clin (Barc)]]></source>
<year>2024</year>
<volume>163</volume>
<numero>Suppl 1</numero>
<issue>Suppl 1</issue>
<page-range>S4-9</page-range></nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Jiang]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Tang]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Pan]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Cheng]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Assessment of the 2023 ACR/EULAR antiphospholipid syndrome classification criteria in a Chinese cohort: Impact on clinical practice]]></article-title>
<source><![CDATA[J Autoimmun]]></source>
<year>2024</year>
<volume>146</volume>
<page-range>103237</page-range></nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="confpro">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Romero]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<source><![CDATA[Pros y contras de los criterios EULAR SAF 2023. Hematología. Número extraordinario]]></source>
<year>2024</year>
<conf-name><![CDATA[ XVI Congreso Argentino de hemostasia y trombosis]]></conf-name>
<conf-loc> </conf-loc>
<page-range>135-40</page-range></nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martínez-Taboada]]></surname>
<given-names><![CDATA[VM]]></given-names>
</name>
<name>
<surname><![CDATA[Gómez]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Merino]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[López-Hoyos]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Del Barrio-Longarela]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Comins-Boo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Are the new 2023 ACR/EULAR classification criteria suitable for advancing the knowledge of obstetric antiphospholipid syndrome?]]></article-title>
<source><![CDATA[Autoimmun Rev]]></source>
<year>2024</year>
<volume>23</volume>
<numero>7-8</numero>
<issue>7-8</issue>
<page-range>103592</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
